These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 34139154)

  • 1. A time-resolved proteomic and prognostic map of COVID-19.
    Demichev V; Tober-Lau P; Lemke O; Nazarenko T; Thibeault C; Whitwell H; Röhl A; Freiwald A; Szyrwiel L; Ludwig D; Correia-Melo C; Aulakh SK; Helbig ET; Stubbemann P; Lippert LJ; Grüning NM; Blyuss O; Vernardis S; White M; Messner CB; Joannidis M; Sonnweber T; Klein SJ; Pizzini A; Wohlfarter Y; Sahanic S; Hilbe R; Schaefer B; Wagner S; Mittermaier M; Machleidt F; Garcia C; Ruwwe-Glösenkamp C; Lingscheid T; Bosquillon de Jarcy L; Stegemann MS; Pfeiffer M; Jürgens L; Denker S; Zickler D; Enghard P; Zelezniak A; Campbell A; Hayward C; Porteous DJ; Marioni RE; Uhrig A; Müller-Redetzky H; Zoller H; Löffler-Ragg J; Keller MA; Tancevski I; Timms JF; Zaikin A; Hippenstiel S; Ramharter M; Witzenrath M; Suttorp N; Lilley K; Mülleder M; Sander LE; ; Ralser M; Kurth F
    Cell Syst; 2021 Aug; 12(8):780-794.e7. PubMed ID: 34139154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal proteomic profiling provides insights into host response and proteome dynamics in COVID-19 progression.
    Lee JS; Han D; Kim SY; Hong KH; Jang MJ; Kim MJ; Kim YG; Park JH; Cho SI; Park WB; Lee KB; Shin HS; Oh HS; Kim TS; Park SS; Seong MW
    Proteomics; 2021 Jun; 21(11-12):e2000278. PubMed ID: 33945677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management.
    Iosef C; Martin CM; Slessarev M; Gillio-Meina C; Cepinskas G; Han VKM; Fraser DD
    J Cell Mol Med; 2023 Jan; 27(1):141-157. PubMed ID: 36537107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study.
    Hu Z; van der Ploeg K; Chakraborty S; Arunachalam PS; Mori DAM; Jacobson KB; Bonilla H; Parsonnet J; Andrews JR; Holubar M; Subramanian A; Khosla C; Maldonado Y; Hedlin H; de la Parte L; Press K; Ty M; Tan GS; Blish C; Takahashi S; Rodriguez-Barraquer I; Greenhouse B; Butte AJ; Singh U; Pulendran B; Wang TT; Jagannathan P
    Elife; 2022 Oct; 11():. PubMed ID: 36239699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19.
    Bi X; Liu W; Ding X; Liang S; Zheng Y; Zhu X; Quan S; Yi X; Xiang N; Du J; Lyu H; Yu D; Zhang C; Xu L; Ge W; Zhan X; He J; Xiong Z; Zhang S; Li Y; Xu P; Zhu G; Wang D; Zhu H; Chen S; Li J; Zhao H; Zhu Y; Liu H; Xu J; Shen B; Guo T
    Cell Rep; 2022 Jan; 38(3):110271. PubMed ID: 35026155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome.
    Merenstein C; Liang G; Whiteside SA; Cobián-Güemes AG; Merlino MS; Taylor LJ; Glascock A; Bittinger K; Tanes C; Graham-Wooten J; Khatib LA; Fitzgerald AS; Reddy S; Baxter AE; Giles JR; Oldridge DA; Meyer NJ; Wherry EJ; McGinniss JE; Bushman FD; Collman RG
    mBio; 2021 Aug; 12(4):e0177721. PubMed ID: 34399607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization by Quantitative Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 Symptomatology.
    Villar M; Urra JM; Rodríguez-Del-Río FJ; Artigas-Jerónimo S; Jiménez-Collados N; Ferreras-Colino E; Contreras M; de Mera IGF; Estrada-Peña A; Gortázar C; de la Fuente J
    Front Immunol; 2021; 12():730710. PubMed ID: 34566994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.
    Penn-Nicholson A; Hraha T; Thompson EG; Sterling D; Mbandi SK; Wall KM; Fisher M; Suliman S; Shankar S; Hanekom WA; Janjic N; Hatherill M; Kaufmann SHE; Sutherland J; Walzl G; De Groote MA; Ochsner U; Zak DE; Scriba TJ;
    PLoS Med; 2019 Apr; 16(4):e1002781. PubMed ID: 30990820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches.
    Ahsan N; Rao RSP; Wilson RS; Punyamurtula U; Salvato F; Petersen M; Ahmed MK; Abid MR; Verburgt JC; Kihara D; Yang Z; Fornelli L; Foster SB; Ramratnam B
    Proteomics; 2021 May; 21(10):e2000279. PubMed ID: 33860983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19.
    Zoodsma M; de Nooijer AH; Grondman I; Gupta MK; Bonifacius A; Koeken VACM; Kooistra E; Kilic G; Bulut O; Gödecke N; Janssen N; Kox M; Domínguez-Andrés J; van Gammeren AJ; Ermens AAM; van der Ven AJAM; Pickkers P; Blasczyk R; Behrens GMN; van de Veerdonk FL; Joosten LAB; Xu CJ; Eiz-Vesper B; Netea MG; Li Y
    Front Immunol; 2022; 13():1027122. PubMed ID: 36405747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma proteomics identify potential severity biomarkers from COVID-19 associated network.
    Sahin AT; Yurtseven A; Dadmand S; Ozcan G; Akarlar BA; Kucuk NEO; Senturk A; Ergonul O; Can F; Tuncbag N; Ozlu N
    Proteomics Clin Appl; 2023 Mar; 17(2):e2200070. PubMed ID: 36217943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated machine learning optimizes and accelerates predictive modeling from COVID-19 high throughput datasets.
    Papoutsoglou G; Karaglani M; Lagani V; Thomson N; Røe OD; Tsamardinos I; Chatzaki E
    Sci Rep; 2021 Jul; 11(1):15107. PubMed ID: 34302024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.
    Suvarna K; Biswas D; Pai MGJ; Acharjee A; Bankar R; Palanivel V; Salkar A; Verma A; Mukherjee A; Choudhury M; Ghantasala S; Ghosh S; Singh A; Banerjee A; Badaya A; Bihani S; Loya G; Mantri K; Burli A; Roy J; Srivastava A; Agrawal S; Shrivastav O; Shastri J; Srivastava S
    Front Physiol; 2021; 12():652799. PubMed ID: 33995121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning.
    Patel MA; Knauer MJ; Nicholson M; Daley M; Van Nynatten LR; Cepinskas G; Fraser DD
    Mol Med; 2023 Feb; 29(1):26. PubMed ID: 36809921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.
    Bauer W; Weber M; Diehl-Wiesenecker E; Galtung N; Prpic M; Somasundaram R; Tauber R; Schwenk JM; Micke P; Kappert K
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic accuracy of MALDI-TOF mass spectrometric analysis of plasma in COVID-19.
    Lazari LC; Ghilardi FR; Rosa-Fernandes L; Assis DM; Nicolau JC; Santiago VF; Dalçóquio TF; Angeli CB; Bertolin AJ; Marinho CR; Wrenger C; Durigon EL; Siciliano RF; Palmisano G
    Life Sci Alliance; 2021 Aug; 4(8):. PubMed ID: 34168074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.
    Kimura Y; Nakai Y; Shin J; Hara M; Takeda Y; Kubo S; Jeremiah SS; Ino Y; Akiyama T; Moriyama K; Sakai K; Saji R; Nishii M; Kitamura H; Murohashi K; Yamamoto K; Kaneko T; Takeuchi I; Hagiwara E; Ogura T; Hasegawa H; Tamura T; Yamanaka T; Ryo A
    Sci Rep; 2021 Oct; 11(1):20638. PubMed ID: 34667241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers.
    Vázquez-Jiménez A; Avila-Ponce De León UE; Matadamas-Guzman M; Muciño-Olmos EA; Martínez-López YE; Escobedo-Tapia T; Resendis-Antonio O
    Front Immunol; 2021; 12():705646. PubMed ID: 34603282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients.
    Shcherbak SG; Anisenkova AY; Mosenko SV; Glotov OS; Chernov AN; Apalko SV; Urazov SP; Garbuzov EY; Khobotnikov DN; Klitsenko OA; Minina EM; Asaulenko ZP
    Front Immunol; 2021; 12():745515. PubMed ID: 34858403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a multiomics model for identification of predictive biomarkers for COVID-19 severity: a retrospective cohort study.
    Byeon SK; Madugundu AK; Garapati K; Ramarajan MG; Saraswat M; Kumar-M P; Hughes T; Shah R; Patnaik MM; Chia N; Ashrafzadeh-Kian S; Yao JD; Pritt BS; Cattaneo R; Salama ME; Zenka RM; Kipp BR; Grebe SKG; Singh RJ; Sadighi Akha AA; Algeciras-Schimnich A; Dasari S; Olson JE; Walsh JR; Venkatakrishnan AJ; Jenkinson G; O'Horo JC; Badley AD; Pandey A
    Lancet Digit Health; 2022 Sep; 4(9):e632-e645. PubMed ID: 35835712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.